The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2014 | Exciting explosion of new drugs in CLL
Speaking to the European Medical Journal at the EHA 2014 meeting, Prof. John Gribben, St Barts Hospital, London, UK, outlines the explosion of new drugs now available for patients based on the increased understanding of CLL disease biology. He outlines the efficacy and safety results from the RESONATE trial with ibrutinib versus Ofatumumab, idelalisib versus rituximab monotherapy study, and data with ABT-199 as monotherapy and in combination with obinutuzumab/GA101. Prof Gribben also comments on resistance observed with ibrutinib.
